A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015

NCT05022771 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: PMG1015 Dose 1
DRUG: PMG1015 Dose 2
DRUG: PMG1015 Dose 3
DRUG: PMG1015 Dose 4
DRUG: PMG1015 Dose 5
DRUG: PMG1015 Dose 6
DRUG: Placebo
DRUG: PMG1015 Dose 7

Sponsor

Pulmongene Ltd.